Compare Enveric Biosciences Inc (ENVB) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.7 (market cap $75.79B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 11328.8× Enveric Biosciences Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.5% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| ENVB | MDLZ | |
|---|---|---|
Market Cap | $6.69M | $75.79B |
Volume | 41,141 | 6,277,523 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $64.99 |
52-Week Low | $1.27 | $51.51 |
Typical Hold Time | 14 Days | 107 Days |
Enterprise Value | -$1.60M | $96.13B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Mondelez International (MDLZ) trades at $60.67, up 1.76% today, with strong analyst support (76% buy ratings) and a $70.29 consensus price target. The stock shows bearish technical signals but maintains solid fundamentals with three consecutive earnings beats and a 8.86% net income margin. Recent dividend increase to $0.52 per share and consistent revenue growth to $38.54B in 2025 highlight operational strength despite cocoa cost pressures.
MDLZ presents a compelling long-term investment with attractive valuation multiples (P/E 21.75, P/S 1.93) and shareholder-friendly policies. Key risks include volatile cocoa prices impacting margins and competitive pressures in the snack food sector. The company's global brand portfolio and emerging market expansion provide growth catalysts, though technical indicators suggest near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
